GRAND RAPIDS, Mich.–(BUSINESS WIRE)–TheraB Medical, a Michigan-based innovator in wearable phototherapy technology for neonatal jaundice, today announced that itGRAND RAPIDS, Mich.–(BUSINESS WIRE)–TheraB Medical, a Michigan-based innovator in wearable phototherapy technology for neonatal jaundice, today announced that it

TheraB Medical Announces Acquisition by Natus Sensory to Expand Access to Innovative Neonatal Phototherapy

2026/02/11 22:01
3 min read

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–TheraB Medical, a Michigan-based innovator in wearable phototherapy technology for neonatal jaundice, today announced that it has been acquired by Natus Sensory, a global leader in sensory and newborn care solutions. The acquisition will enable broader adoption of TheraB’s flagship product, SnugLit, and support Natus Sensory’s mission to provide comprehensive, family-centered care for newborns.

Expanding access to safe, family-centered phototherapy

TheraB Medical’s flagship product, SnugLit, is a wearable phototherapy device designed in accordance with AAP guidelines for the treatment of neonatal jaundice. SnugLit delivers comprehensive body coverage in the familiar form factor of an infant swaddle, eliminating the need for eye protection required with traditional phototherapy. Its portable design supports increased parent interaction, including bonding and breastfeeding, while maintaining continuous therapy. SnugLit is designed to support use across clinical care settings, helping enable continuity of care and family-centered treatment models.

Advancing Newborn Care Through Natus Partnership

“This acquisition validates TheraB’s mission to improve outcomes for infants diagnosed with neonatal jaundice, while Natus Sensory’s global presence in the pediatric community will help expand access to SnugLit’s innovative phototherapy across hospitals and clinical settings,” said Chris Mathia, CEO of TheraB.

Alexa Jones, Founder of TheraB and inventor of SnugLit, added, “TheraB was founded to advance effective jaundice treatment, and SnugLit was developed to preserve the critical bond between mother and baby. Joining Natus Sensory accelerates our path forward, expanding future access for clinicians, hospitals, and families who need it most.”

Expanding how and where effective care can be delivered

“At Natus Sensory, our vision in newborn care is simple and deeply personal: to help give every single baby the best possible start in life,” says Peter Reimer, CEO, Natus Sensory. “TheraB Medical’s wearable phototherapy innovation aligns strongly with that vision. It complements our existing hospital-based solutions while expanding how and where effective care can be delivered – always grounded in real clinical needs and focused on improving outcomes for newborns and their families.”

About TheraB Medical

TheraB Medical is dedicated to improving care for infants diagnosed with neonatal jaundice. Its flagship product, SnugLit, delivers comprehensive body coverage in the familiar form factor of an infant swaddle while eliminating the need for eye protection. Its innovative design allows increased clinician and parent interaction, including breastfeeding, without interrupting therapy. SnugLit’s portable and convenient design supports family-centered care across clinical settings.

TheraB received FDA 510(k) clearance in January 2026 and is backed by various individual angel investors and funds including Red Cedar Ventures, Healthcare Equity Angels, Michigan Rise, Gulf South Angels, Foster Lane Investments, Invest Detroit Ventures, Suncoast Ventures, Smartgate Ventures, 3S Ventures, BakerBridge Ventures, and Wisconsin River Business Angels.

About Natus Sensory

Natus Sensory is a global leader in sensory care, supporting clinicians across hearing, balance, vision, and newborn care. Guided by a belief that meaningful moments begin with a sense, we create trusted solutions that enable confident clinical decisions and improve patient outcomes – from giving every baby the best possible start in life to helping millions of people reconnect with the world through hearing and balance care.

Natus Sensory is an ARCHIMED company.

Contacts

Media: Alexa Jones, Founder, TheraB Medical Products, Inc.
Alexa.Jones@therabmedical.com

Market Opportunity
Grand Base Logo
Grand Base Price(GRAND)
$0.298
$0.298$0.298
0.00%
USD
Grand Base (GRAND) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Term deposit yields inch down on BSP cut bets

Term deposit yields inch down on BSP cut bets

YIELDS on the Bangko Sentral ng Pilipinas’ (BSP) seven-day term deposits edged down on Wednesday amid strong demand as still benign inflation and slow growth fueled
Share
Bworldonline2026/02/12 00:05
‘This Is Not Good for Crypto’: Lawmakers Slam SEC Chair for Easing Industry Policing

‘This Is Not Good for Crypto’: Lawmakers Slam SEC Chair for Easing Industry Policing

The post ‘This Is Not Good for Crypto’: Lawmakers Slam SEC Chair for Easing Industry Policing appeared on BitcoinEthereumNews.com. In brief House Democrats accused
Share
BitcoinEthereumNews2026/02/12 02:04
United States Building Permits Change dipped from previous -2.8% to -3.7% in August

United States Building Permits Change dipped from previous -2.8% to -3.7% in August

The post United States Building Permits Change dipped from previous -2.8% to -3.7% in August appeared on BitcoinEthereumNews.com. Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page. If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet. FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted. The author and FXStreet are not registered investment advisors and nothing in this article is intended…
Share
BitcoinEthereumNews2025/09/18 02:20